| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9226782 | Journal of Allergy and Clinical Immunology | 2005 | 7 Pages |
Abstract
The more marked effect of omalizumab on the LPR and prevention of the repeat-dose priming effect on several inflammatory cell types support a role for anti-IgE treatment in conditions associated with chronic allergic inflammation.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Yee Ean MBBS, Andrew MBBS, Julia Barkans, Farid BSc, Tsen-Teng MD, Sun PhD, A. Barry MD,